Conjugation of Dasatinib with MHI-148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells
- PMID: 31322832
- DOI: 10.1002/cmdc.201900356
Conjugation of Dasatinib with MHI-148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells
Abstract
We hypothesized that conjugation of the near-infrared dye MHI-148 with the anti-leukemia drug dasatinib might produce a potential theranostic for glioblastoma. In fact, the conjugate was found to bind the kinases Src and Lyn, and to inhibit the viability of a glioblastoma cell line with significantly greater potency than dasatinib alone, MHI-148 alone, or a mixture of dasatinib and MHI-148 at the same concentration. It was also used to successfully image a subcutaneous glioblastoma tumor in vivo.
Keywords: cancer; cyanine; glioblastoma; imaging agents; tumor targeting.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
References
-
- J. Yuan, X. Yi, F. Yan, F. Wang, W. Qin, G. Wu, X. Yang, C. Shao, L. W. K. Chung, Mol. Med. Rep. 2015, 11, 821-828.
-
- N. Zhao, C. Zhang, Y. Zhao, B. Bai, J. An, H. Zhang, J. B. Wu, C. Shi, Oncotarget 2016, 7, 57277-57289.
-
- X. Yang, C. Shao, R. Wang, C.-Y. Chu, P. Hu, V. Master, A. O. Osunkoya, H. L. Kim, H. E. Zhau, L. W. K. Chung, J. Urol. 2013, 189, 702-710.
-
- None
-
- X. Yang, C. Shi, R. Tong, W. Qian, H. E. Zhau, R. Wang, G. Zhu, J. Cheng, V. W. Yang, T. Cheng, M. Henary, L. Strekowski, L. W. K. Chung, Clin. Cancer Res. 2010, 16, 2833-2844;
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
